BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37515929)

  • 21. BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor.
    Eckel-Passow JE; Serie DJ; Cheville JC; Ho TH; Kapur P; Brugarolas J; Thompson RH; Leibovich BC; Kwon ED; Joseph RW; Parker AS
    BMC Urol; 2017 Mar; 17(1):19. PubMed ID: 28327121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths.
    Poehlman WL; Hsieh JJ; Feltus FA
    Sci Rep; 2019 Feb; 9(1):2899. PubMed ID: 30814637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.
    Farley MN; Schmidt LS; Mester JL; Pena-Llopis S; Pavia-Jimenez A; Christie A; Vocke CD; Ricketts CJ; Peterson J; Middelton L; Kinch L; Grishin N; Merino MJ; Metwalli AR; Xing C; Xie XJ; Dahia PLM; Eng C; Linehan WM; Brugarolas J
    Mol Cancer Res; 2013 Sep; 11(9):1061-1071. PubMed ID: 23709298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
    Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of BAP1 protein expression in the first metastatic site predicts prognosis in patients with clear cell renal cell carcinoma.
    Miura Y; Inoshita N; Ikeda M; Miyama Y; Oki R; Oka S; Kondoh C; Ozaki Y; Tanabe Y; Kurosawa K; Urakami S; Kohno T; Okaneya T; Takano T
    Urol Oncol; 2017 Jun; 35(6):386-391. PubMed ID: 28284891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BAP1 loss defines a new class of renal cell carcinoma.
    Peña-Llopis S; Vega-Rubín-de-Celis S; Liao A; Leng N; Pavía-Jiménez A; Wang S; Yamasaki T; Zhrebker L; Sivanand S; Spence P; Kinch L; Hambuch T; Jain S; Lotan Y; Margulis V; Sagalowsky AI; Summerour PB; Kabbani W; Wong SW; Grishin N; Laurent M; Xie XJ; Haudenschild CD; Ross MT; Bentley DR; Kapur P; Brugarolas J
    Nat Genet; 2012 Jun; 44(7):751-9. PubMed ID: 22683710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomics and clinical correlates of renal cell carcinoma.
    Mitchell TJ; Rossi SH; Klatte T; Stewart GD
    World J Urol; 2018 Dec; 36(12):1899-1911. PubMed ID: 30099580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular genetics of clear-cell renal cell carcinoma.
    Brugarolas J
    J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.
    Gao X; Jegede O; Gray C; Catalano PJ; Novak J; Kwiatkowski DJ; McKay RR; George DJ; Choueiri TK; McDermott DF; Signoretti S; Bhatt RS
    Clin Genitourin Cancer; 2018 Oct; 16(5):341-348. PubMed ID: 29754934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cooperation and antagonism among cancer genes: the renal cancer paradigm.
    Peña-Llopis S; Christie A; Xie XJ; Brugarolas J
    Cancer Res; 2013 Jul; 73(14):4173-9. PubMed ID: 23832661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiles of renal cell carcinoma in a small Chinese cohort.
    Tai S; Xu DD; Yu Z; Guan Y; Yin S; Xiao J; Xue S; Liang C
    Front Oncol; 2023; 13():1095775. PubMed ID: 37427096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
    Tennenbaum DM; Manley BJ; Zabor E; Becerra MF; Carlo MI; Casuscelli J; Redzematovic A; Khan N; Arcila ME; Voss MH; Feldman DR; Motzer RJ; Benfante NE; Coleman JA; Russo P; Hsieh JJ; Hakimi AA
    Urol Oncol; 2017 Aug; 35(8):532.e7-532.e13. PubMed ID: 28408295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
    Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
    Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of BAP1 expression in metastatic tumor tissue is an event of poor prognosis in patients with metastatic clear cell renal cell carcinoma.
    da Costa WH; Fares AF; Bezerra SM; Morini MA; de Toledo Benigno LA; Clavijo DA; Fornazieri L; Rocha MM; da Cunha IW; de Cassio Zequi S
    Urol Oncol; 2019 Jan; 37(1):78-85. PubMed ID: 30446457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 8q24 clear cell renal cell carcinoma germline variant is associated with VHL mutation status and clinical aggressiveness.
    Eckel-Passow JE; Yan H; Kosel ML; Serie D; Decker PA; Jenkins RB; Costello B; Leibovich B; Ho TH; Parker A
    BMC Urol; 2020 Oct; 20(1):173. PubMed ID: 33121461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.
    Kluzek K; Srebniak MI; Majer W; Ida A; Milecki T; Huminska K; van der Helm RM; Silesian A; Wrzesinski TM; Wojciechowicz J; Beverloo BH; Kwias Z; Bluyssen HAR; Wesoly J
    Oncotarget; 2017 Apr; 8(17):28558-28574. PubMed ID: 28212566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma.
    Wang Z; Peng S; Guo L; Xie H; Wang A; Shang Z; Niu Y
    Clin Chim Acta; 2018 Nov; 486():9-17. PubMed ID: 30006290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.